Reverse Vaccine Strikes Blow Against Type I Diabetes
Tolerion Inc. reported Phase II results showing promising disease-modifying activity of its lead product TOL-3021 against Type I diabetes.
The product preserved pancreatic beta-cell function while reducing T-cell activity in patients with the disease, as published in Science Translational Medicine.
The product is a "reverse" vaccine designed to selectively suppress specific elements of the immune system that are inappropriately activated in Type I diabetes.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter